Clinical Trial Update: Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients [Phase 2]

View source ↗

Summary

Phase 2 trial updating Difluoromethylornithine (DFMO) for chemoprevention of skin cancer in organ transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Organ Transplant Recipients
• Skin Neoplasms

Drugs mentioned

• Difluoromethylornithine (DFMO) (difluoromethylornithine)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Post-solid Organ Transplant, Skin Neoplasms | Phase 2 | Status: COMPLETED